QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
Positive News Sentiment  
NASDAQ:MLYS

Mineralys Therapeutics - MLYS Stock Forecast, Price & News

$14.85
-0.02 (-0.13%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$14.25
▼
$15.25
50-Day Range
N/A
52-Week Range
$13.52
▼
$21.98
Volume
247,536 shs
Average Volume
284,418 shs
Market Capitalization
$606.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.20

Mineralys Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
143.8% Upside
$36.20 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$25.10 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.96) to ($5.36) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

225th out of 999 stocks

Pharmaceutical Preparations Industry

93rd out of 489 stocks

See Top Rated MarketRank™ Stocks Here

MLYS stock logo

About Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.

Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLYS Stock News Headlines

March 18, 2023 | finanznachrichten.de
Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 18, 2023 | markets.businessinsider.com
Credit Suisse Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)
March 29, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
March 16, 2023 | msn.com
Where Mineralys Therapeutics Stands With Analysts
March 15, 2023 | finance.yahoo.com
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 7, 2023 | msn.com
Mineralys gains as Wells Fargo, Stifel issue bullish ratings citing lead asset
March 4, 2023 | finance.yahoo.com
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
March 1, 2023 | finance.yahoo.com
Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
March 29, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
February 20, 2023 | finance.yahoo.com
Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023
See More Headlines
Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLYS Company Calendar

Today
3/29/2023
Next Earnings (Estimated)
6/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MLYS
CUSIP
N/A
CIK
1933414
Web
www.mineralystx.com
Phone
888-378-6240
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.20
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+143.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
40,857,000
Free Float
N/A
Market Cap
$606.73 million
Optionable
Not Optionable
Beta
N/A














MLYS Stock - Frequently Asked Questions

Should I buy or sell Mineralys Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MLYS shares.
View MLYS analyst ratings or view top-rated stocks.

What is Mineralys Therapeutics' stock price forecast for 2023?

6 brokers have issued 1-year target prices for Mineralys Therapeutics' stock. Their MLYS share price forecasts range from $27.00 to $45.00. On average, they predict the company's stock price to reach $36.20 in the next twelve months. This suggests a possible upside of 143.8% from the stock's current price.
View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts.

How have MLYS shares performed in 2023?

Mineralys Therapeutics' stock was trading at $18.44 on January 1st, 2023. Since then, MLYS shares have decreased by 19.5% and is now trading at $14.85.
View the best growth stocks for 2023 here.

When is Mineralys Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 21st 2023.
View our MLYS earnings forecast.

When did Mineralys Therapeutics IPO?

(MLYS) raised $180 million in an initial public offering on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share.

What is Mineralys Therapeutics' stock symbol?

Mineralys Therapeutics trades on the NASDAQ under the ticker symbol "MLYS."

When did the company's quiet period expire?

Mineralys Therapeutics' quiet period expired on Wednesday, March 22nd. Mineralys Therapeutics had issued 12,000,000 shares in its public offering on February 10th. The total size of the offering was $192,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Mineralys Therapeutics?

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mineralys Therapeutics' stock price today?

One share of MLYS stock can currently be purchased for approximately $14.85.

How much money does Mineralys Therapeutics make?

Mineralys Therapeutics (NASDAQ:MLYS) has a market capitalization of $606.73 million.

How can I contact Mineralys Therapeutics?

The official website for the company is www.mineralystx.com. The company can be reached via phone at 888-378-6240 or via email at investorrelations@mineralystx.com.

This page (NASDAQ:MLYS) was last updated on 3/29/2023 by MarketBeat.com Staff